
Sign up to save your podcasts
Or


We’re focusing on a challenging topic: anticoagulation in CKD patients with atrial fibrillation. With up to 25% of CKD patients affected, managing this common arrhythmia is no easy task. How do we balance stroke prevention and bleeding risks? What’s the role of DOACs versus vitamin K antagonists? And should dialysis patients even receive anticoagulation? Are there any new treatment options? To help us untangle these questions, we’re joined by Frida Welander from Karolinska University, Sweden, an expert on the field. Don’t miss this insightful discussion.
By European Renal Association3
22 ratings
We’re focusing on a challenging topic: anticoagulation in CKD patients with atrial fibrillation. With up to 25% of CKD patients affected, managing this common arrhythmia is no easy task. How do we balance stroke prevention and bleeding risks? What’s the role of DOACs versus vitamin K antagonists? And should dialysis patients even receive anticoagulation? Are there any new treatment options? To help us untangle these questions, we’re joined by Frida Welander from Karolinska University, Sweden, an expert on the field. Don’t miss this insightful discussion.

7,617 Listeners

325 Listeners

498 Listeners

3,360 Listeners

1,143 Listeners

14 Listeners

369 Listeners

172 Listeners

84 Listeners

374 Listeners

8 Listeners

135 Listeners

327 Listeners